» Articles » PMID: 20586959

Early Loss to Follow Up After Enrolment in Pre-ART Care at a Large Public Clinic in Johannesburg, South Africa

Overview
Date 2010 Jul 1
PMID 20586959
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate loss to follow up (LTFU) between initial enrollment and the first scheduled return medical visit of a pre-antiretroviral therapy (ART) care program for patients not eligible for ART.

Methods: The study was conducted at a public-sector HIV clinic in Johannesburg. We reviewed records of all patients newly enrolled in the pre-ART care program and not yet eligible for ART between January 2007 and February 2008. Crude proportions of patients completing their first return medical visit stratified by patient characteristics were calculated. A modified-Poisson approach was used to estimate directly relative risks of returning for their first return medical visit within 1 year adjusting for patient characteristics as potential confounders.

Results: A total of 356 patients were identified. Two-thirds had a CD4 count > 350 cells/microl (median [IQR] CD4 = 458 [394, 585]) and were scheduled to return in 6 months for a first medical visit. Seventy-four percent of these patients did not return within one year for this visit. The remaining 36% of all patients had a baseline CD4 count 251-350 cells/microl and were scheduled to return in 3 months. Only 6% of these patients returned within 4 months; 41% returned within one year. Relative risks were positively associated with a patient being employed and negatively associated with the baseline CD4 count.

Conclusions: Given the high rate of LTFU immediately after enrolling in pre-ART care, it is clear that care programs are not expediting the timely initiation of ART. Significantly improved adherence to pre-ART care and monitoring for patients not yet eligible for ART is required for South Africa to achieve its AIDS strategy goals and reduce the problem of late presentation and initiation of ART.

Citing Articles

Sociobehavioral Risk Factors and Clinical Implications of Late Presentation Among People Living with HIV in the Brazilian Amazon Region.

Pereira L, Franca E, Costa I, Lima I, Freire A, Ramos F AIDS Behav. 2024; 28(10):3404-3420.

PMID: 38992229 PMC: 11427532. DOI: 10.1007/s10461-024-04437-5.


Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment-How to Interpret Discrepancies Between Different Studies.

Labhardt N, Brown J, Sass N, Ford N, Rosen S Clin Infect Dis. 2023; 77(8):1176-1184.

PMID: 37229594 PMC: 10573746. DOI: 10.1093/cid/ciad317.


Trajectories of re-engagement: factors and mechanisms enabling patient return to HIV care in Zambia.

Beres L, Mwamba C, Bolton-Moore C, Kennedy C, Simbeza S, Topp S J Int AIDS Soc. 2023; 26(2):e26067.

PMID: 36840391 PMC: 9958345. DOI: 10.1002/jia2.26067.


Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis.

Larson B, Pascoe S, Huber A, Long L, Murphy J, Miot J PLoS One. 2021; 16(3):e0248551.

PMID: 33735206 PMC: 7971492. DOI: 10.1371/journal.pone.0248551.


Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study.

Onoya D, Sineke T, Hendrickson C, Mokhele I, Maskew M, Long L BMJ Open. 2020; 10(3):e030228.

PMID: 32213514 PMC: 7170559. DOI: 10.1136/bmjopen-2019-030228.


References
1.
Mshana G, Wamoyi J, Busza J, Zaba B, Changalucha J, Kaluvya S . Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: a qualitative study of early rural referrals to the national program. AIDS Patient Care STDS. 2006; 20(9):649-57. DOI: 10.1089/apc.2006.20.649. View

2.
Makombe S, Jahn A, Tweya H, Chuka S, Yu J, Hochgesang M . A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. PLoS One. 2007; 2(7):e620. PMC: 1905945. DOI: 10.1371/journal.pone.0000620. View

3.
McNutt L, Wu C, Xue X, Hafner J . Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157(10):940-3. DOI: 10.1093/aje/kwg074. View

4.
Bassett I, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J . Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009; 51(2):135-9. PMC: 2747614. DOI: 10.1097/qai.0b013e3181a44ef2. View

5.
Horne R, Cooper V, Gellaitry G, Date H, Fisher M . Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007; 45(3):334-41. DOI: 10.1097/QAI.0b013e31806910e3. View